T&P, thanks for your supportive comments. I give credit to Paul Hopper for being part of the assembly of Imugene. Axel Hoos also deserving of mention as founder, who was obviously not agreeable with the direction of the company and found himself on the receiving end of a hatchet job from Hopper. Unfortunately, since AH was axed, the company has not been able to give shareholders any great rewards. It has however given management huge increases in pay and share equity. Make no mistake, Paul Hopper is a selfish character, who will serve himself ahead of others. That’s ok, although a very limiting flaw on a personal basis etc. My gripe is not really knowing he’s a particularly greedy and selfish type, it’s simply that he doesn’t really provide any current function or value to the business, and worse than that, he may well be bad for business. His only task now is capital management and he is failing consistently. Too many shares on issue, and a poorly constructed institutional register=fail. Yes we have a healthy working capital bank balance, but it’s not translated to any rewards as a shareholder really. If Hopper can’t do anything broader than marking time for shareholders whilst seeing himself with Imugene staff are overpaid, his time as a deserving leader has expired, it’s over.
(20min delay)